Can step counts predict prostate cancer treatment success?
NCT ID NCT06660862
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study looks at how daily step counts change in 80 vulnerable adults with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus standard hormone therapy. Researchers want to see if physical activity levels relate to treatment safety and quality of life over 6 months. Participants must be 18 or older and show signs of frailty on a geriatric assessment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
o University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.